Secukinumab reduce ACE 2
Secukinumab and Expression of ACE2 in Affected Skin of Patients With Psoriasis
TAKE-HOME MESSAGE
Angiotensin-converting enzyme 2 (ACE2) is the receptor used for entry by the SARS-CoV-2 virus. The authors analyzed mRNA expression of ACE2 in the serum and skin biopsies of psoriasis patients versus controls from the ObePso-S trial, which studied the effects of secukinumab on systemic inflammatory markers. At baseline, ACE2 levels were upregulated in affected psoriatic skin with IL-17 driven inflammation. With secukinumab inhibiting IL-17 inflammation, keratinocyte ACE2 levels decreased.
- It is not clear whether the response of keratinocytes to secukinumab is indicative of the response of other epithelial linings and whether these changes decrease SARS-CoV-2 entry. The study demonstrates the continually evolving body of knowledge on treating patients with psoriasis with biologics in the era of COVID-19.
– Margaret Hammond, MD
Abstract
Secukinumab reduced the inflammation and the expression of ACE2, which encodes the SARS-CoV-2 receptor, in plaques of patients with psoriasis. Reductions in ACE2 expression with secukinumab significantly correlated with reductions in disease activity.
Secukinumab Lowers Expression of ACE2 in Affected Skin of Patients With Psoriasis
J. Allergy Clin. Immunol 2020 Sep 28;[EPub Ahead of Print], JG Krueger, DF Murrell, S Garcet, K Navrazhina, PC Lee, E Muscianisi, A BlauveltSent from my iPhone
Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574
Please excuse the shortness of this message, as it has been sent from
a mobile device.
Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
Skin Care Physicians of Costa Rica
Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574
Please excuse the shortness of this message, as it has been sent from
a mobile device.
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home